• Caspase 3/7 Drive Cytoprotective Autophagy in Breast Cancer

  2026-07-08

  This study uncovers a conserved, non-apoptotic role for caspase 3 and caspase 7 in promoting cytoprotective autophagy and DNA damage response during non-lethal stress in human breast cancer cells. The findings reshape our understanding of stress adaptation mechanisms and highlight implications for targeting caspase pathways in cancer therapy.

• VX-765: Precision Caspase-1 Inhibition for Inflammation Rese

  2026-07-08

  VX-765 stands out as a potent, selective caspase-1 inhibitor that enables researchers to dissect inflammatory and pyroptotic pathways with unmatched specificity. Its proven efficacy extends from cell-based cytokine assays to in vivo models of neuroinflammation, unlocking new insights into barrier function, cytokine modulation, and disease pathogenesis.

• Optimizing Cell Assays with KU-60019: Data-Driven Protocols

  2026-07-07

  This article delivers a scenario-driven, evidence-based exploration of KU-60019 (SKU A8336) for biomedical researchers. Emphasizing experimental reproducibility and data interpretation, it addresses real-world issues in cell viability, proliferation, and cytotoxicity assays. Researchers will gain actionable insights into ATM kinase inhibition, radiosensitization, and protocol optimization using KU-60019.

• Exendin-4: Protocol-Driven Insights for Type 2 Diabetes Rese

  2026-07-07

  Exendin-4 (Exenatide) enables robust, reproducible modeling of insulin sensitivity, beta cell function, and hepatic steatosis reversal in both in vitro and in vivo systems. This article details workflow enhancements, troubleshooting tips, and recent innovations—highlighting how APExBIO’s Exendin-4 empowers advanced type 2 diabetes research.

• Lamotrigine for Advanced Sodium Channel and 5-HT Inhibition

  2026-07-06

  Lamotrigine empowers high-fidelity sodium channel and serotonin pathway studies across CNS and cardiac models. With proven solubility and purity, it enables reproducible workflows from BBB permeability assays to epilepsy-induced arrhythmia research.

• GSK2606414: Selective PERK Inhibitor for ER Stress Research

  2026-07-06

  GSK2606414 is a potent, nanomolar-range PERK inhibitor enabling precise modulation of ER stress and unfolded protein response pathways. Its selectivity and oral bioavailability make it a benchmark tool for cancer and neurodegenerative disease models. APExBIO supplies GSK2606414 as a research-grade compound, with robust evidence supporting its use in mechanistic studies.

• Sodium Nitroprusside: Strategic Mechanisms for Sex-Differenc

  2026-07-05

  This article illuminates the multifaceted role of Sodium Nitroprusside as a nitric oxide donor, highlighting its mechanistic basis, translational value, and strategic deployment in sex-difference hypertension research. Drawing from landmark studies and expert workflows, it provides actionable guidance for translational scientists aiming to model, dissect, and ultimately target the complex interplay between vascular smooth muscle relaxation, platelet function, and hormonal influences.

• Protease Inhibitor Cocktail EDTA-Free: Precision for Viral F

  2026-07-04

  Explore how the Protease Inhibitor Cocktail EDTA-Free enables uncompromised protein extraction for research on pH-sensitive viral fusion and phosphorylation, offering workflow insights and scientific depth not found in typical product guides.

• Targeting AR/ARv7 in TNBC: EPI-001 Blocks Metastatic Pathway

  2026-07-03

  This study delineates how androgen receptor (AR) and its splice variant ARv7 are linked to poor prognosis in triple-negative breast cancer (TNBC) and demonstrates that targeting these receptors with EPI-001 disrupts key metastatic and EMT pathways. The findings provide mechanistic insight into AR/ARv7-driven TNBC progression and inform future strategies for targeted intervention.

• GW4064: Illuminating FXR-Driven Bile Acid and Metabolic Netw

  2026-07-03

  Explore GW4064, a non-steroidal FXR agonist, as an advanced tool for dissecting the bile acid metabolism pathway and lipid regulatory networks. This article uniquely bridges transporter biology, tight junction integrity, and translational assay design for metabolic research.

• LAMP1 Regulates CXCL10-CXCR3-Driven Macrophage Polarization

  2026-07-02

  This study uncovers how LAMP1 modulates the CXCL10-CXCR3 axis to direct macrophage polarization under both inflammatory and non-inflammatory conditions. The findings clarify the role of autophagy in immune regulation and demonstrate how Poly(I:C), a synthetic double-stranded RNA analog, can shift these cellular dynamics, offering new insights for targeted immunomodulation.

• ML133 HCl in Pulmonary Vascular Remodeling: A Translational

  2026-07-02

  Explore how ML133 HCl, a selective potassium channel inhibitor, uniquely advances pulmonary artery smooth muscle cell proliferation research. This article offers a deep dive into mechanistic innovation and assay design, setting it apart from standard reviews.

• Practical Use of Cathepsin B inhibitor CA-074 in Disease Mod

  2026-07-01

  Cathepsin B inhibitor CA-074 (SKU A1926) is a selective small molecule tool to block cathepsin B activity in cell-based and in vivo experiments, providing mechanistic clarity in studies of cancer metastasis, neurotoxicity, and immune response modulation. It is not intended for applications requiring inhibition of other cathepsins or for long-term storage in solution. Researchers should follow product-specific handling and solubility guidance to ensure reliable outcomes.

• Cytochalasin D: Actin Polymerization Inhibitor in Nanopartic

  2026-07-01

  Cytochalasin D empowers researchers to dissect actin-dependent processes, optimize nanoparticle uptake assays, and interrogate cell cycle dynamics with precision. By leveraging its potent, selective mechanism, labs can enhance reproducibility and gain mechanistic insight across oncology, virology, and drug delivery workflows.

• Bacterial Effector RipAF1 Targets Plant FNR to Suppress ATP

  2026-06-30

  The reference study reveals that Ralstonia solanacearum’s effector RipAF1 directly interacts with plant ferredoxin-NADP+ reductase (FNR), inhibiting ATP production and weakening plant immunity. This work uncovers a new virulence strategy, highlighting ATP’s centrality in plant defense and pathogen-host dynamics.

406 records 9/28 page Previous Next First page 上5页 678910 下5页 Last page